Acute Liver Failure Treatment: New Research Points to Protein CPS1
Acute liver failure treatment has long been limited by a shortage of effective therapeutic options. With more than 2,000 Americans dying from the condition each year, the need for new approaches is urgent. Now, researchers at the University of Michigan have identified an unexpected mechanism by which the body may naturally attempt to protect and repair the liver following severe injury, opening a potential pathway toward entirely new acute liver failure treatment strategies.
What Is Acute Liver Failure
The liver performs hundreds of essential functions every day. When a severe injury destroys enough liver cells in a short period of time, such as from a toxic overdose of acetaminophen, the organ can fail rapidly. Unlike chronic liver disease, which develops over years, acute liver failure can occur within days and carries a high mortality rate when acute liver failure treatment options are insufficient.
At FOMAT, hepatology is one of our most active therapeutic areas, and acute liver failure represents one of the most urgent unmet needs we encounter in clinical research. Discoveries like this one from the University of Michigan point toward entirely new pathways for acute liver failure treatment that could change how trials in this space are designed and executed.
The Role of CPS1 in Liver Protection
The University of Michigan research, published in the Proceedings of the National Academy of Sciences, centers on a protein called CPS1, short for carbamoyl phosphate synthetase 1. Under normal circumstances, CPS1 plays a key role in breaking down ammonia inside the mitochondria of hepatocytes, the primary cells of the liver.
What the research team, led by Bishr Omary, MD, discovered was that CPS1 has an entirely separate function that was not previously understood. When liver cells are damaged, CPS1 is released into the bloodstream. There it is taken up by immune cells called monocytes, which it then reprograms to become anti inflammatory and directs toward the liver to support repair.
“CPS1 that is cleared from blood reprograms monocytes to become anti inflammatory and move to the liver,” Omary said. “This cytokine like function, which is entirely unrelated to its usual enzymatic function, provides a mechanism for the protective effect we observed. It is very exciting since it offers a potential pathway to developing new acute liver failure treatment approaches for all different types of the condition.”
Testing CPS1 as a Therapeutic
Researcher Min Jung Park led the laboratory work of studying CPS1 in blood, bone marrow, liver, and bile samples from mice. To test its potential as an acute liver failure treatment, the team injected mice with an additional supply of CPS1 generated in the lab before exposing them to high doses of acetaminophen capable of causing acute liver injury.
Mice that received the added CPS1 prior to acetaminophen exposure did not suffer major liver damage. When CPS1 was injected after the high dose was administered, the animals’ livers showed significant signs of recovery. A modified form of CPS1 that lacked its normal ammonia processing function performed equally well as an anti inflammatory agent, confirming that the immune triggering effect operates independently of its enzymatic role.
“The amount of CPS1 released to blood naturally is not sufficient to cope with injury, which is why the boost becomes very helpful,” Park explained. “In contrast, if too much is spilled to blood by the liver, then this means too many liver cells have died to have a chance to recover.”
CPS1 as a Monitoring Tool
Beyond its potential as an acute liver failure treatment, CPS1 also shows promise as a diagnostic monitoring tool. Earlier research by the same team found that blood levels of CPS1 rise and fall in a pattern that correlates directly with the extent of liver damage, making it a potential early marker for recovery from acute liver injury. This dual role, both therapeutic and diagnostic, makes CPS1 a particularly compelling target for further investigation.
What Comes Next
Omary notes that CPS1 is a large protein, and future work will focus on identifying which of its components are most responsible for triggering the anti inflammatory response. His team is continuing to assess how the mechanism works in mice and whether it can ultimately be applied in humans. Significantly more research will be required before human use can be confirmed, but the findings represent a meaningful advance in understanding acute liver failure treatment at the molecular level.
FOMAT’s Role in Hepatology Research
Translating discoveries like this into approved therapies requires clinical trial sites with deep hepatology expertise, strong patient networks, and the operational infrastructure to execute complex studies. FOMAT supports sponsors and CROs in conducting hepatology and gastroenterology trials across the United States, providing access to diverse patient populations and experienced investigator teams.
To learn more about our digestive diseases capabilities or explore our active studies, visit fomatmedical.com. For additional information on acute liver failure, visit Mayo Clinic.